Lineage Cell Therapeutics Newsroom

D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3

BenzingaNov 18 10:13 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaNov 18 10:12 ET

Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Announces Target Price $4

Moomoo NewsNov 15 09:33 ET

Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating

Moomoo NewsNov 14 09:34 ET

Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating

Moomoo NewsNov 13 09:32 ET

Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating

Moomoo NewsNov 12 09:31 ET

Craig-Hallum Initiates Lineage Cell Therapeutics(LCTX.US) With Buy Rating

Moomoo NewsNov 11 09:33 ET

Baird Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsOct 1 14:32 ET

Craig-Hallum Initiates Lineage Cell Therapeutics at Buy With $4 Price Target

MT NewswiresAug 21 05:29 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaAug 20 08:48 ET

Craig-Hallum Initiates Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Announces Target Price $4

Moomoo NewsAug 20 08:33 ET

Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline Progress

TipRanksAug 13 09:52 ET

Lineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical Progress

TipRanksAug 10 10:37 ET

B.Riley Financial Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsJul 25 15:32 ET

Buy Rating Affirmed for Lineage Cell Therapeutics on Promising OpRegen Trials and Strategic Roche Partnership

TipRanksJul 25 15:17 ET

Buy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA Patients

TipRanksMay 8 00:41 ET

Maintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership With Roche

TipRanksMay 6 17:01 ET

Lineage Cell Therapeutics Analyst Ratings

BenzingaMay 6 10:41 ET

Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release

TipRanksMar 19 01:50 ET

Buy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy Advancements

TipRanksMar 11 00:40 ET